Group 1 - The core point of the article is that Juzhi Biotechnology (02367) has seen a significant stock price increase following its inclusion in the MSCI China All Shares Index, which will take effect after the market closes on February 29, 2024 [1] - Juzhi Biotechnology is recognized as a leader in the domestic recombinant collagen industry, leveraging strong academic and research capabilities to achieve breakthroughs in recombinant collagen preparation technology [1] - The market for recombinant collagen is projected to grow substantially, with retail sales expected to rise from 10.8 billion yuan in 2021 to 108.3 billion yuan by 2027, reflecting a compound annual growth rate (CAGR) of 46.9% [1] Group 2 - The company is positioned as a frontrunner in the recombinant collagen sector, with significant technological barriers to entry [1] - Juzhi Biotechnology's brands, Kefu Mei and Keli Jin, are expected to continue expanding their market share through a diverse product matrix and comprehensive channel strategies [1] - The company's successful positioning in the medical aesthetics sector is anticipated to enable it to rapidly capture opportunities in the recombinant collagen injection market [1]
港股异动 | 巨子生物(02367)早盘涨超5% 获纳入MSCI中国全股票指数 机构称重组胶原蛋白发展前景广阔